On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...
Zacks.com on MSN22h
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
Stocktwits on MSN2d
Arrowhead, Sarepta Stocks Rise Despite Price-Target Cuts Post $1B Licensing Deal: Retail Buzz StrongShares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...
Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Arrowhead has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics for rare genetic disease ...
William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.Don't Miss our Black Friday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback